Beijing Mabworks Biotech Co., Ltd. announced a private placement of 2,095,558 common shares at a price of CNY 71.58 for gross proceeds of CNY 150,000,041.64 on August 1, 2023. The transaction will include participation from new investor, received CNY Betta Pharmaceuticals Co., Ltd. for 2.91% stake. The transaction has been approved by the 6th session of the company?s 4th directorate and the 4th session of the company?s 4th supervisory board.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.95 CNY | +0.57% | +5.32% | -14.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.74% | 2.54B | |
+6.52% | 71.18B | |
+11.33% | 9.23B | |
-11.55% | 5B | |
+48.05% | 4.46B | |
+5.09% | 3.95B | |
+20.00% | 2.44B | |
-24.89% | 2.36B | |
+21.45% | 2.18B | |
+7.64% | 1.67B |
- Stock Market
- Equities
- 300558 Stock
- News Betta Pharmaceuticals Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.